home / stock / aezs:cc / aezs:cc news

AEZS:CC News and Press, Aeterna Zentaris Inc. From 08/03/22

Stock Information
Company Name: Aeterna Zentaris Inc.
Stock Symbol: AEZS:CC
Market: TSXC
Website: zentaris.com
Menu
AEZS:CC AEZS:CC Quote AEZS:CC Short AEZS:CC News AEZS:CC Articles AEZS:CC Message Board
Get AEZS:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
AEZS:CC - Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent Highlights

– Company ended the quarter with $58.2 million in cash – Driving c ontinued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (Nasdaq:...
AEZS:CC - Aeterna Zentaris Announces Effective Date of Share Consolidation

TORONTO, ON, July 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“ Aeterna ” or the “ Company ”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced t...

AEZS:CC - Aeterna Zentaris Announces Shareholder Approval of Share Consolidation

TORONTO, ONTARIO, July 15, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (" Aeterna " or the " Company "), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today an...

AEZS:CC - Aeterna Zentaris Announces Further Adjournment of Shareholder Meeting

TORONTO, ONTARIO, July 06, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (" Aeterna " or the " Company "), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today an...
AEZS:CC - Aeterna Zentaris Announces Results of Annual Meeting of Shareholders

- Vote to approve share consolidation adjourned to July 6, 2022 TORONTO, ONTARIO, June 21, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (" Aeterna " or the " Company "), a specialty biopharmaceutical company developing and commercializing a d...

AEZS:CC - Aeterna Zentaris Achieves Proof-of-Concept for the Treatment of NMOSD with AIM Biologicals Program

– Company advancing AIM Biologicals development program as a potential therapeutic treatment option for neuromyelitis optica spectrum disorder ("NMOSD") – Positive r esults presented at the 13 th International Congress ...

AEZS:CC - Aeterna Zentaris to Present at the JMP Securities Life Sciences Conference

Live vid eo webcast on Wednesday, June 15 th at 12:30 PM ET TORONTO, ONTARIO, June 09, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company de...
AEZS:CC - Aeterna Zentaris' Licensing Partner, Consilient Health Announces European Launch of Ghryvelin(TM) (macimorelin) for Diagnosing Adult Growth Hormone Deficiency

TORONTO, ONTARIO, May 25, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic pro...

AEZS:CC - Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference

TORONTO, ONTARIO, May 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic pro...

AEZS:CC - Aeterna Zentaris Announces Virtual 2022 Meeting of Shareholders and Urges Shareholders to Vote in Favor of the Proposed Share Consolidation

TORONTO, ON, May 16, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“ Aeterna ” or the “ Company ”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced th...
Previous 10 Next 10